These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 20164685)

  • 1. What is the difference between triple-negative and basal breast cancers?
    Seal MD; Chia SK
    Cancer J; 2010; 16(1):12-6. PubMed ID: 20164685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of triple negative breast cancer (TNBC): current options and future perspectives.
    De Laurentiis M; Cianniello D; Caputo R; Stanzione B; Arpino G; Cinieri S; Lorusso V; De Placido S
    Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S80-6. PubMed ID: 21129616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Triple negative breast carcinoma and the basal phenotype: from expression profiling to clinical practice.
    Diaz LK; Cryns VL; Symmans WF; Sneige N
    Adv Anat Pathol; 2007 Nov; 14(6):419-30. PubMed ID: 18049131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Triple-negative/basal-like breast cancer: clinical, pathologic and molecular features.
    Venkitaraman R
    Expert Rev Anticancer Ther; 2010 Feb; 10(2):199-207. PubMed ID: 20131996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Basal-HER2 phenotype shows poorer survival than basal-like phenotype in hormone receptor-negative invasive breast cancers.
    Liu H; Fan Q; Zhang Z; Li X; Yu H; Meng F
    Hum Pathol; 2008 Feb; 39(2):167-74. PubMed ID: 18045647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidermal growth factor receptor in triple-negative and basal-like breast cancer: promising clinical target or only a marker?
    Burness ML; Grushko TA; Olopade OI
    Cancer J; 2010; 16(1):23-32. PubMed ID: 20164687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical significance of basal-like subtype in triple-negative breast cancer.
    Yamamoto Y; Ibusuki M; Nakano M; Kawasoe T; Hiki R; Iwase H
    Breast Cancer; 2009; 16(4):260-7. PubMed ID: 19701681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Possible treatment strategies for triple-negative breast cancer on the basis of molecular characteristics.
    Kurebayashi J
    Breast Cancer; 2009; 16(4):275-80. PubMed ID: 19408071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinicopathological characteristics of triple-negative breast cancers.
    Sasaki Y; Tsuda H
    Breast Cancer; 2009; 16(4):254-9. PubMed ID: 19657711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Triple-negative breast cancer: molecular features, pathogenesis, treatment and current lines of research.
    Bosch A; Eroles P; Zaragoza R; Viña JR; Lluch A
    Cancer Treat Rev; 2010 May; 36(3):206-15. PubMed ID: 20060649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What is triple-negative breast cancer?
    Irvin WJ; Carey LA
    Eur J Cancer; 2008 Dec; 44(18):2799-805. PubMed ID: 19008097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Are triple-negative and basal-like breast cancer synonymous?
    Rakha E; Ellis I; Reis-Filho J
    Clin Cancer Res; 2008 Jan; 14(2):618; author reply 618-9. PubMed ID: 18223240
    [No Abstract]   [Full Text] [Related]  

  • 13. [Triple-negative breast carcinoma--rewiev of current literature].
    Rubovszky G; Udvarhelyi N; Horváth Z; Láng I; Kásler M
    Magy Onkol; 2010 Dec; 54(4):325-35. PubMed ID: 21163763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metastatic triple-negative breast cancer.
    Rakha EA; Chan S
    Clin Oncol (R Coll Radiol); 2011 Nov; 23(9):587-600. PubMed ID: 21524569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Triple-negative breast cancer: role of the androgen receptor.
    Gucalp A; Traina TA
    Cancer J; 2010; 16(1):62-5. PubMed ID: 20164692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Basal cytokeratin and epidermal growth factor receptor expression are not predictive of BRCA1 mutation status in women with triple-negative breast cancers.
    Collins LC; Martyniak A; Kandel MJ; Stadler ZK; Masciari S; Miron A; Richardson AL; Schnitt SJ; Garber JE
    Am J Surg Pathol; 2009 Jul; 33(7):1093-7. PubMed ID: 19390427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes.
    Kim MJ; Ro JY; Ahn SH; Kim HH; Kim SB; Gong G
    Hum Pathol; 2006 Sep; 37(9):1217-26. PubMed ID: 16938528
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacotherapy of triple-negative breast cancer.
    Arslan C; Dizdar O; Altundag K
    Expert Opin Pharmacother; 2009 Sep; 10(13):2081-93. PubMed ID: 19640211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Triple-negative breast cancer: making the most of a misnomer.
    McCarthy N; Mitchell G; Bilous M; Wilcken N; Lindeman GJ
    Asia Pac J Clin Oncol; 2012 Jun; 8(2):145-55. PubMed ID: 22524573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frequently increased epidermal growth factor receptor (EGFR) copy numbers and decreased BRCA1 mRNA expression in Japanese triple-negative breast cancers.
    Toyama T; Yamashita H; Kondo N; Okuda K; Takahashi S; Sasaki H; Sugiura H; Iwase H; Fujii Y
    BMC Cancer; 2008 Oct; 8():309. PubMed ID: 18950515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.